354 related articles for article (PubMed ID: 25780077)
1. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.
Martinón-Torres F; Czajka H; Center KJ; Wysocki J; Majda-Stanislawska E; Omeñaca F; Bernaola Iturbe E; Blazquez Gamero D; Concheiro-Guisán A; Gimenez-Sanchez F; Szenborn L; Giardina PC; Patterson S; Gruber WC; Scott DA; Gurtman A
Pediatrics; 2015 Apr; 135(4):e876-86. PubMed ID: 25780077
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
[TBL] [Abstract][Full Text] [Related]
5. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
Weckx LY; Thompson A; Berezin EN; de Faria SM; da Cunha CA; Pride M; Patterson S; Gruber WC; Emini EA; Scott DA;
Vaccine; 2012 Dec; 30(52):7566-72. PubMed ID: 23099331
[TBL] [Abstract][Full Text] [Related]
6. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
[TBL] [Abstract][Full Text] [Related]
8. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
[TBL] [Abstract][Full Text] [Related]
9. Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants.
Martinón-Torres F; Wysocki J; Center KJ; Czajka H; Majda-Stanislawska E; Omeñaca F; Concheiro-Guisan A; Gimenez-Sanchez F; Szenborn L; Blázquez-Gamero D; Moreno-Galarraga L; Giardina PC; Sun G; Gruber WC; Scott DA; Gurtman A
Pediatr Infect Dis J; 2017 Mar; 36(3):326-332. PubMed ID: 27902652
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.
Odusanya OO; Kuyinu YA; Kehinde OA; Francois N; Yarzabal JP; Moreira M; Borys D; Schuerman L
Niger Postgrad Med J; 2013 Dec; 20(4):272-81. PubMed ID: 24633268
[TBL] [Abstract][Full Text] [Related]
12. Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.
Rouers EDM; Bruijning-Verhagen PCJ; van Gageldonk PGM; van Dongen JAP; Sanders EAM; Berbers GAM
JAMA; 2020 Sep; 324(11):1068-1077. PubMed ID: 32930758
[TBL] [Abstract][Full Text] [Related]
13. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of age.
Gadzinowski J; Tansey SP; Wysocki J; Kopińska E; Majda-Stanisławska E; Czajka H; Korbal P; Pietrzyk JJ; Baker SA; Giardina PC; Gruber WC; Emini EA; Scott DA
Pediatr Infect Dis J; 2015 Feb; 34(2):180-5. PubMed ID: 25126854
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.
Togashi T; Okada K; Yamaji M; Thompson A; Gurtman A; Cutler M; Aizawa M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2015 Oct; 34(10):1096-104. PubMed ID: 26121200
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
19. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
Rodgers GL; Esposito S; Principi N; Gutierrez-Brito M; Diez-Domingo J; Pollard AJ; Snape MD; Martinón-Torres F; Gruber WC; Patterson S; Thompson A; Gurtman A; Paradiso P; Scott DA
Vaccine; 2013 Oct; 31(42):4765-74. PubMed ID: 23965217
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.
Bryant KA; Gurtman A; Girgenti D; Reisinger K; Johnson A; Pride MW; Patterson S; Devlin C; Gruber WC; Emini EA; Scott DA
Pediatr Infect Dis J; 2013 Apr; 32(4):383-8. PubMed ID: 23104129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
